From the American Academy of Ophthalmology

Investigators used data from the CATT study to determine the baseline predictors of visual acuity outcomes one year after treatment with ranibizumab or bevacizumab for wet AMD. Confirming results from previous trials of ranibizumab, the following were independently associated with less visual acuity improvement: older age, better baseline visual acuity, larger CNV area, predominantly or minimally classic lesion, absence of RAP lesions, presence of GA, greater total fovea thickness, and RPE elevation on OCT.  The authors say these predictors should not be used to justify reduced interest in treatment because all subgroups experienced some visual benefit. Instead, use the predictors to adjust patient expectations. Ophthalmology, January 2013